Avicanna Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
37
- Stock Symbol
-
AVCN
- Investments
-
4
- Share Price
-
$0.06
- (As of Wednesday Closing)
Avicanna General Information
Description
Avicanna Inc is a commercial-stage international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for the medical and pharmaceutical market segments. It has three operating segments: Canada, International, and Corporate. It generates the majority of its revenue from Canada.
Contact Information
Website
www.avicanna.comCorporate Office
- 480 University Avenue
- Suite 1502
- Toronto, Ontario M5G 1V2
- Canada
Corporate Office
- 480 University Avenue
- Suite 1502
- Toronto, Ontario M5G 1V2
- Canada
Avicanna Timeline
Avicanna Stock Performance
As of 18-Nov-2026, Avicanna’s stock price is $0.06. Its current market cap is $8.22M with 134M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.06 | $0.06 | $0.06 - $0.20 | $8.22M | 134M | 182K | -$0.02 |
Avicanna Financials Summary
As of 30-Jun-2026, Avicanna has a trailing 12-month revenue of $18.3M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 17,079 | 25,288 | 28,087 | 27,894 |
| Revenue | 18,314 | 18,218 | 18,565 | 12,434 |
| EBITDA | (2,155) | (1,405) | (2,474) | (5,447) |
| Net Income | (2,763) | (2,034) | (2,912) | (6,474) |
| Total Assets | 16,980 | 15,510 | 13,527 | 16,562 |
| Total Debt | 119 | 0 | 76 | 1,359 |
Avicanna Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Avicanna Comparisons
Industry
Financing
Details
Avicanna Competitors (2)
One of Avicanna’s 2 competitors is Quantum BioPharma, a Corporation company based in Toronto, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Quantum BioPharma | Corporation | Toronto, Canada | ||||
| Lite Strategy | Corporation | San Diego, CA |
Avicanna Patents
Avicanna Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3239914-A1 | Oral cannabinoid compositions and methods for treating neurological diseases and disorders | Pending | 03-Dec-2021 | ||
| US-20250032520-A1 | Oral cannabinoid compositions and methods for treating neurological diseases and disorders | Pending | 03-Dec-2021 | ||
| WO-2023100138-A1 | Oral cannabinoid compositions and methods for treating neurological diseases and disorders | Inactive | 03-Dec-2021 | ||
| WO-2023047308-A1 | Methods for reducing or eliminating incidence of seizures and sudden unexpected death in epilepsy | Inactive | 22-Sep-2021 | ||
| US-12064461-B2 | Deep penetrating topical cannabinoid compositions and methods for treating musculoskeletal inflammation and pain | Active | 16-Jul-2021 | A61K36/3482 |
Avicanna Signals
Avicanna Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Avicanna Investments & Acquisitions (4)
Avicanna’s most recent deal was a Merger/Acquisition with MyMedi.ca for . The deal was made on 31-Jul-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MyMedi.ca | 31-Jul-2023 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Sigma Magdalena | 08-Aug-2019 | Joint Venture | Laboratory Services (Healthcare) | ||
| Sativa Nativa | 31-Dec-2018 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Santa Marta Golden Hemp | 16-Aug-2018 | Merger/Acquisition | Cultivation |
Avicanna ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Avicanna Exits (1)
Avicanna’s most recent exit was on 31-Dec-2018 from Sativa Nativa. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Sativa Nativa | 31-Dec-2018 | Completed |
|
Avicanna Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| MyMedi.ca | Toronto, Canada | 2019 |
Avicanna FAQs
-
When was Avicanna founded?
Avicanna was founded in 2016.
-
Where is Avicanna headquartered?
Avicanna is headquartered in Toronto, Canada.
-
What is the size of Avicanna?
Avicanna has 37 total employees.
-
What industry is Avicanna in?
Avicanna’s primary industry is Drug Discovery.
-
Is Avicanna a private or public company?
Avicanna is a Public company.
-
What is Avicanna’s stock symbol?
The ticker symbol for Avicanna is AVCN.
-
What is the current stock price of Avicanna?
As of 18-Nov-2026 the stock price of Avicanna is $0.06.
-
What is the current market cap of Avicanna?
The current market capitalization of Avicanna is $8.22M.
-
What is Avicanna’s current revenue?
The trailing twelve month revenue for Avicanna is $18.3M.
-
Who are Avicanna’s competitors?
Quantum BioPharma and Lite Strategy are competitors of Avicanna.
-
What is Avicanna’s annual earnings per share (EPS)?
Avicanna’s EPS for 12 months was -$0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process